Dermata Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Balance Sheet Details (Tables)

6 Months Ended

Jun. 30, 2023

	June 30,		December 31,
	2023		2022
Prepaid expenses and other current assets:
Prepaid insurance	$	146,221	$	586,407
Prepaid research and development costs		66,712		92,581
Prepaid other		60,628		11,604
Interest receivable		790		12,602
Total prepaid expenses and other current assets	$	274,351	$	703,194

Accrued and other current liabilities:
Accrued research and development costs	$	33,070	$	254,787
Accrued compensation and benefits		181,967		170,389
Accrued legal fees		22,000		-
Accrued other		8,047		756
Total accrued and other current liabilities	$	245,084	$	425,932